Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-BLP25 (Stimuvax) vaccine in rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
2011-000847-25Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tecemotide in rectal adenocarcinoma (2 arms), sponsored by Merck KGaA. Primary endpoints: Intratumoral MUC1-specific immune parameters and Peripheral antigen-specific immune responses. Started Jun 2011; status: completed.
02
Drugs
tecemotide
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2011-000847-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000847-25.